文献速递乳腺癌

HR阳性HER2阴性转移性乳腺癌老年与年轻女性治疗及生存趋势:法国ESME多中心真实世界队列

Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort.
PubMed 文献 · Eur J Cancer · 2025-12-05

基于法国ESME多中心真实世界队列17,830例HR+/HER2-转移性乳腺癌女性,分析CDK4/6抑制剂引入前后一线治疗与生存的年龄差异。≥70岁患者内分泌联合CDK4/6i使用率从0.9%升至48.9%,化疗使用持续低于年轻患者;两年龄组rwPFS均改善,≥70岁患者OS改善至34.0-37.3个月但仍短于年轻患者。

要点

  • CDK4/6i时代两年龄组内分泌联合CDK4/6i使用率均大幅上升至约50%
  • ≥70岁患者一线化疗使用率始终低于<70岁患者
  • 两年龄组rwPFS均改善,但≥70岁患者OS仍短于年轻患者

核心结论

  • CDK4/6i引入后HR+/HER2-转移性乳腺癌一线内分泌联合CDK4/6i使用率升至约50%,化疗下降,两年龄组rwPFS和≥70岁患者OS均改善。
  • 观察性设计无法确认生存改善与治疗变化的因果关系。

研究设计与样本

  • 基于法国ESME数据库(NCT03275311)的多中心真实世界队列研究,纳入18个法国综合癌症中心连续起始一线治疗的HR+/HER2-转移性乳腺癌女性。
  • 共纳入17,830例合格女性,中位年龄62岁,按年龄(<70岁;70岁及以上)和诊断时期(CDK4/6i前/后)分层分析。

主要发现

  • ≥70岁女性较少表现为侵袭性疾病特征。
  • 内分泌联合CDK4/6i使用率在≥70岁女性从0.9%升至48.9%,在<70岁女性从0.8%升至50.1%(两组均p<0.001)。
  • 一线化疗(单药或联合)使用率从52.7%降至30.0%(p<0.001),≥70岁女性始终低于<70岁女性:2016年前32.2% vs 61.1%,2017年后16.4% vs 36.5%(均p<0.001)。
  • ≥70岁女性OS随时间改善(34.0-37.3个月,p=0.03),但仍短于年轻女性。
  • 两年龄组rwPFS均改善:≥70岁女性从12.6个月至14.8个月,<70岁女性从12.3个月至14.4个月(两组均p<0.001)。

关键数值与推荐

  • 2017年后内分泌联合CDK4/6i使用率升至约50%,近期体能状态好的女性中达约70%,但体能状态差的老年患者仍约50%。
  • 需要更广泛地采用内分泌联合CDK4/6i并减少化疗使用。

临床怎么用

  • HR+/HER2-转移性乳腺癌一线治疗应优先考虑内分泌联合CDK4/6i,尤其体能状态好的患者。
  • 老年患者化疗使用率较低,但体能状态差者CDK4/6i联合内分泌治疗使用仍不足,需个体化评估后扩大获益人群。

局限性

  • 观察性设计,无法确认治疗与生存改善之间的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To describe first-line treatments, overall (OS) and real-world progression-free (rwPFS) survival in women with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) following introduction of CDK4/6 inhibitors (CDK4/6i), according to age (<70; 70 +) and diagnostic period (before/after CDK4/6i). METHODS: We extracted data from the ESME database (NCT03275311) which includes consecutive patients starting first-line mBC in one of the 18 French Comprehensive cancer centres. RESULTS: We identified 17,830 eligible women (median age: 62 years). Women aged ≥ 70 years were less likely to present with aggressive disease characteristics. Use of endocrine therapy combined with CDK4/6i increased substantially over time in both age groups, from 0.9 % to 48.9 % in 70 + women, and from 0.8 % to 50.1 % in women < 70 (p < 0.001 for both). In contrast, first-line chemotherapy (alone or in combination) declined from 52.7 % to 30.0 % (p < 0.001), with consistently lower use among women 70 + compared to those < 70: 32.2 % vs. 61.1 % prior to 2016, and 16.4 % vs. 36.5 % after 2017 (p < 0.001 for both). Among 70 + women, OS improved over time (34.0-37.3 months, p = 0.03) but remained shorter than in younger women. rwPFS improved in both age groups: from 12.6 to 14.8 months in 70 + women, and from 12.3 to 14.4 months in women < 70 (p < 0.001 for both). CONCLUSION: ET+CDK4/6i use rose up to ∼50 % after 2017, reaching ∼70 % in recent years among women with good PS, but remained ∼50 % in older patients with poor PS. Broader adoption is needed, with less chemotherapy use. Survival outcomes have improved but, causality cannot be confirmed due to the observational design.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bouteiller F, Gourgou S, Bringuier M, et al. Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort. Eur J Cancer. 2025. PMID: 41411883. doi:10.1016/j.ejca.2025.116166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。